Xilio Therapeutics, Inc. (NASDAQ:XLO) announced promising updated Phase 2 results for its investigational therapy vilastobart, combined with atezolizumab, in heavily pre-treated patients with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Strategy adds 1,045 Bitcoin after $112M stock sale originally appeared on TheStreet. MicroStrategy Inc., now operating as Strategy, has announced a significant update regarding its capital-raising ...

TALLAHASSEE, Fla. — Florida taxpayers are expected to save $1.3 billion in the next fiscal year under the tax package passed by state lawmakers this week. It was the tax package that was largely ...

INDIANAPOLIS — The Oklahoma City Thunder had a comeback of their own. Trailing for most of the game, looking exhausted and exasperated, and facing a 10-point deficit late in the third quarter ...

TUCSON, Ariz. (KVOA) - As Tucson grapples with a surge in homicide rates compared to last year, residents are demanding action. News 4 Tucson has been covering the crime crisis from all angles ...

A controversial former member of the Miami Dolphins signed an extension on Monday night. Safety DeShon Elliott signed a two-year, $12.5 million extension, including $9.21 million in guarantees ...

WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...